Literature DB >> 12724322

Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4.

Caroline A Jefferies1, Sarah Doyle, Cornelia Brunner, Aisling Dunne, Elizabeth Brint, Claudia Wietek, Eva Walch, Thomas Wirth, Luke A J O'Neill.   

Abstract

In this study we have identified members of the Toll-like receptor (TLR) family (namely, TLRs 4, 6, 8, and 9) as proteins to which the intracellular protein tyrosine kinase, Bruton's tyrosine kinase (Btk), binds. Detailed analysis of the interaction between Btk and TLR8 demonstrates that the presence of both Box 2 and 3 motifs in the Toll/interleukin-1 receptor domain was required for the interaction. Furthermore, co-immunoprecipitation experiments revealed that Btk can also interact with key proteins involved in TLR4 signal transduction, namely, MyD88, Mal (MyD88 adapter-like protein), and interleukin-1 receptor-associated kinase-1, but not TRAF-6. The ability of Btk to interact with TLR4 and Mal suggests a role for Btk in lipopolysaccharide (LPS) signal transduction. Stimulation of the human monocytic cell line THP-1 with LPS resulted in an increase in the level of tyrosine phosphorylation of Btk (indicative of activation). The autokinase activity of Btk was also stimulated after LPS stimulation. In addition, a dominant negative form of Btk inhibited TLR4-mediated activation of a nuclear factor kappaB (NFkappaB)-dependent reporter gene in HEK293 cells as well as LPS-induced activation of NFkappaB in the astrocytoma cell line U373 and the monocytic cell line RAW264.7. Further investigation revealed that the Btk-specific inhibitor, LFM-A13, inhibited the activation of NFkappaB by LPS in THP-1 cells. Our findings implicate Btk as a Toll/interleukin-1 receptor domain-binding protein that is important for NFkappaB activation by TLR4.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724322     DOI: 10.1074/jbc.M301484200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  116 in total

1.  Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia.

Authors:  María Edith González-Serrano; Iris Estrada-García; Dolores Mogica-Martínez; Alejandro González-Garay; Gabriela López-Herrera; Laura Berrón-Ruiz; Sara Elva Espinosa-Padilla; Marco Antonio Yamazaki-Nakashimada; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Sergio Antonio Estrada-Parra; Francisco J Espinosa-Rosales
Journal:  J Clin Immunol       Date:  2012-06-05       Impact factor: 8.317

2.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.

Authors:  Ofer Levy; Eugénie E Suter; Richard L Miller; Michael R Wessels
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

Review 3.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

Review 4.  Subversion of innate immune signaling through molecular mimicry.

Authors:  Tsan Sam Xiao
Journal:  J Clin Immunol       Date:  2010-06-30       Impact factor: 8.317

5.  Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3.

Authors:  Yuko Kawakami; Naoki Inagaki; Shahram Salek-Ardakani; Jiro Kitaura; Hiroyuki Tanaka; Koichi Nagao; Yu Kawakami; Wenbin Xiao; Hiroichi Nagai; Michael Croft; Toshiaki Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

6.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 8.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

9.  Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL.

Authors:  Dola Sengupta; Alicia Koblansky; Jennifer Gaines; Tim Brown; A Phillip West; Dekai Zhang; Tak Nishikawa; Sung-Gyoo Park; R Martin Roop; Sankar Ghosh
Journal:  J Immunol       Date:  2009-12-14       Impact factor: 5.422

Review 10.  Toll-like receptor signaling in cell proliferation and survival.

Authors:  Xinyan Li; Song Jiang; Richard I Tapping
Journal:  Cytokine       Date:  2009-09-22       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.